Nature Communications (May 2021)

Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric cancer

  • Wengui Shi,
  • Gengyuan Zhang,
  • Zhijian Ma,
  • Lianshun Li,
  • Miaomiao Liu,
  • Long Qin,
  • Zeyuan Yu,
  • Lei Zhao,
  • Yang Liu,
  • Xue Zhang,
  • Junjie Qin,
  • Huili Ye,
  • Xiangyan Jiang,
  • Huinian Zhou,
  • Hui Sun,
  • Zuoyi Jiao

DOI
https://doi.org/10.1038/s41467-021-23053-8
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 19

Abstract

Read online

Resistance to Trastuzumab in HER2 gastric cancer patients remains a clinical challenge. In this study, the authors demonstrate that HER2 promotes tumorigenesis in gastric cancer by regulating mitotic progression through a Shc1-SHCBP1-PLK1-MISP axis and they identify a compound, TFBG, able to disrupt SHCBP1/PLK1 interaction and to synergize with trastuzumab.